Your browser is no longer supported. Please, upgrade your browser.
Lantern Pharma Inc.
Index- P/E- EPS (ttm)-1.12 Insider Own36.82% Shs Outstand10.07M Perf Week-5.57%
Market Cap154.52M Forward P/E- EPS next Y-1.43 Insider Trans0.00% Shs Float6.37M Perf Month-11.81%
Income-7.90M PEG- EPS next Q-0.26 Inst Own27.20% Short Float3.63% Perf Quarter-15.70%
Sales- P/S- EPS this Y-135.90% Inst Trans73.40% Short Ratio1.67 Perf Half Y-10.66%
Book/sh8.11 P/B1.86 EPS next Y-32.40% ROA-20.90% Target Price- Perf Year-
Cash/sh7.95 P/C1.90 EPS next 5Y- ROE-21.60% 52W Range10.40 - 24.84 Perf YTD-21.61%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-39.25% Beta-
Dividend %- Quick Ratio124.10 Sales past 5Y- Gross Margin- 52W Low45.10% ATR1.26
Employees11 Current Ratio124.10 Sales Q/Q- Oper. Margin- RSI (14)43.33 Volatility8.70% 7.65%
OptionableYes Debt/Eq0.00 EPS Q/Q-207.60% Profit Margin- Rel Volume0.31 Prev Close15.62
ShortableYes LT Debt/Eq0.00 EarningsMay 03 AMC Payout- Avg Volume138.37K Price15.09
Recom1.50 SMA20-3.68% SMA50-12.85% SMA200-9.43% Volume43,485 Change-3.39%
May-10-21 06:35AM  
May-03-21 04:32PM  
Apr-29-21 07:00AM  
Apr-26-21 04:30PM  
Apr-06-21 07:45AM  
Apr-01-21 07:59AM  
Mar-25-21 02:45PM  
Mar-23-21 07:48AM  
Mar-22-21 09:10AM  
Mar-17-21 07:00AM  
Mar-12-21 09:00AM  
Mar-11-21 03:21AM  
Mar-10-21 04:00PM  
Mar-03-21 07:00AM  
Feb-22-21 08:52AM  
Feb-16-21 06:35AM  
Jan-20-21 04:00PM  
Jan-14-21 09:30PM  
Jan-06-21 04:20AM  
Jan-04-21 07:00AM  
Dec-17-20 07:00AM  
Dec-15-20 07:00AM  
Dec-11-20 02:32AM  
Dec-08-20 08:32AM  
Nov-24-20 09:30AM  
Nov-10-20 04:53AM  
Oct-29-20 03:59PM  
Oct-22-20 07:00AM  
Oct-19-20 11:35AM  
Oct-05-20 07:46AM  
Sep-22-20 07:55AM  
Sep-11-20 11:46AM  
Sep-04-20 06:01PM  
Aug-27-20 07:55AM  
Aug-18-20 01:29PM  
Aug-14-20 02:25PM  
Aug-05-20 09:00AM  
Jul-30-20 06:57AM  
Jul-24-20 07:56AM  
Jul-20-20 07:55AM  
Jul-16-20 11:00AM  
Jun-29-20 08:45AM  
Jun-17-20 09:23AM  
Jun-15-20 03:53PM  
Jun-11-20 08:12AM  
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.